Overview

Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients

Status:
Unknown status

Trial end date:
2019-01-01

Target enrollment:

Participant gender:

Summary

A phase III multicenter, randomized study with Lenalidomide (Revlimid®) maintenance versus observation after intensified induction regimen containing rituximab followed by high dose chemotherapy and Autologous Stem Cell Transplantation as first line treatment in adult patients with advanced Mantle Cell Lymphoma: IIL study (MCL0208).

Phase:

Phase 3

Details

Lead Sponsor:

Fondazione Italiana Linfomi ONLUS

Treatments:

Lenalidomide
Rituximab
Thalidomide